# NCT04479306 (NCT04479306)

> Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04479306
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions: Alisertib; Osimertinib; Sapanisertib
- Enrollment: 37
- Primary outcome: Recommended phase 2 dose (RP2D) of osimertinib and alisertib combination (Arm A)
- Primary outcome: RP2D of osimertinib and sapanisertib combination (Arm B)
- Primary outcome: Dose-limiting toxicity (DLT)
- Primary outcome: Incidence of adverse events

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04479306